DY
FBRX icon

Dowling & Yahnke’s Forte Biosciences FBRX Stock Holding History

Dowling & Yahnke’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-46
Closed -$114K – 307
2019
Q2 		$114K Buy
46
+14
+44% +$41.5K 0.01% 291
2019
Q1 		$132K Buy
+32
New +$124K 0.01% 254
2018
Q1 		– Sell
-44
Closed -$169K – 287
2017
Q4 		$169K Buy
+44
New +$176K 0.02% 289

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dowling & Yahnke's FBRX Position: Q3 2019 in Review

Dowling & Yahnke sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 46 shares — an estimated $114K sold.

Dowling & Yahnke first reported a position in FBRX in Q4 2017 and held it in 3 quarters. The position peaked at $169K in Q4 2017. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Dowling & Yahnke reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Dowling & Yahnke sold 46 Forte Biosciences shares in Q3 2019, an estimated $114K.
  • Dowling & Yahnke first reported a position in Forte Biosciences in Q4 2017 and held it in 3 quarters.
  • Dowling & Yahnke's Forte Biosciences position peaked at $169K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Dowling & Yahnke's 13F filing for Q3 2019, filed 29 Oct 2019.